AstraZeneca plc (AZN) Receives “Buy” Rating from Bryan, Garnier & Co
Bryan, Garnier & Co restated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Monday morning. They currently have a GBX 5,220 ($63.62) target price on the biopharmaceutical company’s stock.
Several other brokerages have also recently weighed in on AZN. JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 4,900 ($59.72) price objective (up from GBX 4,800 ($58.50)) on shares of AstraZeneca plc in a research note on Monday, August 8th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,800 ($70.69) price objective on shares of AstraZeneca plc in a research note on Monday, August 8th. Jefferies Group set a GBX 5,400 ($65.81) price objective on shares of AstraZeneca plc and gave the stock a neutral rating in a research note on Monday, August 8th. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($48.75) price objective on shares of AstraZeneca plc and gave the stock a sell rating in a research note on Wednesday, August 10th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca plc has a consensus rating of Hold and a consensus price target of GBX 4,960.13 ($60.45).
AstraZeneca plc (LON:AZN) opened at 5027.00 on Monday. The firm’s 50-day moving average is GBX 4,994.82 and its 200 day moving average is GBX 4,488.47. The stock’s market capitalization is GBX 63.59 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.